updated chart, page-49

I totally agree. But I think the read outs on the PTX 100 Basket study trial and the PTX 200 AML trials will be a few years ahead of the CarT for Breast and Ovarian treatments.

Patients on the trial for PTX 100 are already showing extended survival than predicted. And this is from low dose early in the phase 1. PTX 200 has already reported 3 CRs with the phase 2b AML trial. Its safety has improved after trial redesign. And it has FDA ODD already.

Either of these two are company makers by themselves. Add to that the OmniCar potential and PTX shows huge potential for its low market cap.

Keep in mind RACs market cap when at 5c was much lower than where PTX is now. So although I am looking forward to a PTX rerate, I think we have to be realistic in expectations.